GT Biopharma (NASDAQ:GTBP – Get Free Report) and Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.
This table compares GT Biopharma and Bolt Biotherapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares GT Biopharma and Bolt Biotherapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GT Biopharma||N/A||N/A||-$20.88 million||($0.30)||-0.79|
|Bolt Biotherapeutics||$7.20 million||4.98||-$88.10 million||($1.89)||-0.50|
Institutional & Insider Ownership
8.1% of GT Biopharma shares are owned by institutional investors. Comparatively, 73.6% of Bolt Biotherapeutics shares are owned by institutional investors. 10.0% of GT Biopharma shares are owned by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
GT Biopharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for GT Biopharma and Bolt Biotherapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
GT Biopharma presently has a consensus target price of $3.50, indicating a potential upside of 1,386.20%. Bolt Biotherapeutics has a consensus target price of $5.67, indicating a potential upside of 499.65%. Given GT Biopharma’s higher probable upside, equities analysts clearly believe GT Biopharma is more favorable than Bolt Biotherapeutics.
Bolt Biotherapeutics beats GT Biopharma on 9 of the 13 factors compared between the two stocks.
About GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.